Healthcare

Immuron Limited (ASX:IMC) develops and commercialises orally delivered polyclonal antibodies derived from hyperimmune bovine colostrum for gastrointestinal disease prevention and treatment. Its operations combine the Travelan productBusinesswith clinical development programs, including IMM-529. FY26 disclosures provide an updated picture of sales performance, development activities and …

In March 2026, an independent monitoring committee recommended stopping the Phase III TACTI-004 study in first-line non-small cell lung cancer after a planned interim futility analysis. Immutep (ASX:IMM) subsequently ceased enrolment and began winding down the study. The outcome does not establish efficacy for …

The company’s portfolio includes the Vision-MR ablation catheter and the Advantage-MR system, which are associated with MRI-guided electrophysiology procedures. MRI provides anatomical imaging during intervention, while catheter technology delivers the tools required for mapping and treatment. Actual hospital implementation depends on equipment availability, compatible …

The update follows the formal minutes from Acrux's end-of-Phase II meeting with the FDA. Two adequate and well-controlled 24-week Phase III trials are expected to demonstrate efficacy and support approval, with a further 28 weeks of data to inform long-term safety.

Echo IQ has filed a request for supervisory review, a form of administrative appeal, of the FDA's decision. The FDA has accepted the appeal, and the agency's ombudsman has been informed.

Careteq Limited (ASX:CTQ) is an Australian healthcare technology company focused on medication management and digital healthcare coordination. Its current business activities centre on HMR Referrals, a platform designed to connect general practitioners with accredited pharmacists for Home Medicines Reviews. Following the divestment of its …

Genetic Signatures Limited (ASX:GSS) is an Australian molecular diagnostics company specialising in infectious disease detection. Its proprietary 3base technology supports the development of EasyScreen diagnostic products, designed to identify multiple pathogens through molecular testing. The company's operations include product development, manufacturing, clinical validation and …